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T
obacco smoking causes high rates of mortality and morbidity throughout the world. Despite the availability of smoking-
cessation medications, maintenance of long-term abstinence is difficult, and most individuals who attempt to quit smok-
ing relapse. Although tobacco smoke contains many substances, researchers and policymakers agree that nicotine is a major 
cause of tobacco dependence. Understanding the neural substrates of nicotine dependence is essential for the development of 
more effective antismoking medications than those currently available. This article focuses on the neural substrates, especially 
nicotinic acetylcholine receptors, that mediate the reinforcing effects of nicotine and the development of nicotine dependence. 
Neuroadaptations in the function of the neurotransmitters dopamine, glutamate, and gamma-aminobutyric acid (GABA), which 
have been shown to be critically involved in nicotine dependence, are also reviewed. Finally, the article discusses progress in the 
discovery and development of smoking-cessation medications. 
T
obacco dependence is a major public health problem that results in 
significant morbidity, mortality, and health care costs for both smokers 
and society. The health benefits of smoking cessation are well-known, 
and nearly 40 percent of smokers in the United States try to quit each year.  Nev-
ertheless, only approximately 3 to 6 percent of those who attempt to quit suc-
ceed in avoiding smoking for 6 to 12 months, with the majority of quit attempts 
failing within the first 8 days (Hughes et al., 2004). Professionally administered 
smoking-cessation therapy improves the odds of a successful quit attempt, but its 
effectiveness is limited by a lack of highly effective medications. To date, the only 
smoking-cessation medications approved by the Food and Drug Administration 
(FDA) are nicotine replacement therapy (NRT), bupropion (Wellbutrin/Zyban), 
and varenicline (Chantix), along with the second-line agents nortriptyline and 
clonidine. Of these treatments, varenicline appears to be most effective, yielding 
abstinence rates of approximately 22 percent at the end of 1 year, compared with 
9 percent with placebo (Gonzales et al., 2006). For a comprehensive review of 
current smoking-cessation medications, see Nides (2008).
  An understanding of the neural substrates (structures and processes) that main-
tain nicotine dependence is essential for the development of effective smoking-
cessation medications. Although people probably do not smoke solely to obtain 
nicotine—some of tobacco’s 4,000 other chemical ingredients, as well as sensory and conditioned effects, may also contribute to the 
habit—nicotine certainly plays a major role in tobacco 
dependence (Stolerman and Jarvis, 1995; Rose, 2006). 
This review discusses: (1) the interaction of nicotine 
with neuronal pathways in the brain that leads to the   
initiation and maintenance of the tobacco-smoking habit, 
(2) the adaptations in several neurotransmitter systems 
that result from chronic nicotine exposure and lead to 
continued smoking and the development of nicotine 
dependence, and (3) the implications of these interac-
tions and neuroadaptations for the design and discovery 
of novel smoking-cessation treatments.
THREE PHASES OF NICOTINE DEPENDENCE
Nicotine dependence is characterized by three phases: 
•		Acquisition and maintenance of nicotine-taking behavior: 
In humans, the administration of nicotine through 
tobacco smoking produces a mild pleasurable rush, 
mild euphoria, increased arousal, decreased fatigue, and 
relaxation (Henningfield et al., 1985). These reinforc-
ing effects play an important role in the initiation and 
maintenance of tobacco smoking (Watkins et al., 2000; 
Markou, 2008). Several other species, such as rats and 
nonhuman primates, exhibit behavioral evidence of 
nicotine reinforcement by reliably self-administering 
intravenous nicotine (Rose and Corrigall, 1997).
•	 Withdrawal symptoms upon cessation of nicotine intake: 
Chronic nicotine use induces neuroadaptations in the 
brain’s reward system that result in the development 
of nicotine dependence. Thus, nicotine-dependent 
smokers must continue nicotine intake to avoid  dis-
tressing somatic and affective withdrawal symptoms. 
Newly abstinent smokers experience symptoms such as 
depressed mood, anxiety, irritability, difficulty concen-
trating, craving, bradycardia, insomnia, gastrointestinal 
discomfort, and weight gain (Shiffman and Jarvik, 
1976; Hughes et al., 1991). Experimental animals, 
such as rats and mice, exhibit a nicotine withdrawal 
syndrome that, like the human syndrome,  includes 
both somatic signs and a negative affective state (Wat-
kins et al., 2000; Malin et al., 2006). The somatic 
signs of nicotine withdrawal include rearing, jumping, 
shakes, abdominal constrictions, chewing, scratch-
ing, and facial tremors. The negative affective state 
of nicotine withdrawal is characterized by decreased 
responsiveness to previously rewarding stimuli, a state 
called anhedonia.
•	Vulnerability to relapse: Abstinent smokers remain prone 
to relapse for weeks, months, or even years after ces-
sation of tobacco smoking. Resumption of smoking, 
like relapse to other drugs of abuse, often occurs upon 
exposure to people, places, objects, or other stimuli that 
individuals have learned to associate with the positive 
rewarding effects of the drug (Hughes et al., 2004). 
Stress and cigarette smoking itself can also precipitate 
resumption of habitual smoking.
Comprehensive medication therapy for nicotine 
dependence will have to target all three phases of drug 
dependence. Whether by a single “magic bullet” or a 
sequential strategy using multiple medications, such 
therapy will need to attenuate the reinforcing effects 
of nicotine, alleviate the negative affective and somatic 
symptoms of withdrawal, strengthen abstinence behav-
iors, and block relapse to smoking. To do so, the medi-
cation or medications will need to act upon the neuro-
biological substrates that underlie each of those aspects 
of nicotine dependence. The remainder of this review 
focuses on our current knowledge of these substrates 
and their potential as targets for smoking-cessation 
medications.
THE ROLE OF NICOTINIC RECEPTORS
Nicotine influences mood, cognition, and body func-
tion by binding to and activating nicotinic acetylcholine 
receptors (nAChRs) located on neurons in the brain 
(Figures 1 and 2). When activated by either nicotine 
or the endogenous neurotransmitter acetylcholine, the 
nAChR opens a channel that allows ions to pass through 
the neuron’s membrane from the exterior to the interior 
of the cell and trigger changes that activate the cell. In 
this section, we examine the interactions of nicotine 
with nAChRs and the possibility of treating nicotine 
dependence by altering these interactions.
Nicotine produces rewarding effects by interacting 
with nAChRs on neurons in the brain’s mesolimbic 
reward system. This system comprises dopaminergic 
neurons that originate in the ventral tegmental area 
(VTA) and release the neurotransmitter dopamine in 
regions  involved in information processing, memory, 
and emotions, such as the nucleus accumbens (NAc), 
hippocampus, amygdala, and prefrontal cortex (PFC). 
Increases in dopamine levels within the mesolimbic 
system give rise to rewarding effects. Nicotine directly 
enhances dopamine levels in the mesolimbic system by 
interacting with nAChRs on the dopaminergic neurons 
and causing γthem to release more of the neurotrans-
mitter (Balfour, 2009; Barrett et al., 2004; Koob and 
Volkow, 2010). Nicotine also modulates dopamine 
RESEARCH REVIEWS—NEURAL MECHANISMS OF NICOTINE DEPENDENCE • 5
Nicotine influ-
ences mood, 
cognition, and 
body func  tion 
by activating 
nicotinic acetyl-
choline recep-
tors located on 
neurons in the 
brain.6 • ADDICTION SCIENCE & CLINICAL PRACTICE—JULY 2011
release indirectly by binding to nAChRs located on 
excitatory glutamatergic and inhibitory gamma amino-
butyric acid (GABAergic) neurons in the VTA. These 
glutamatergic and GABAergic neurons originate from a 
number of brain areas, such as the NAc, hippocampus, 
PFC, amygdala, ventral pallidum, and pedunculopontine 
tegmental nucleus, and regulate the activity of dopami-
nergic neurons.
In contrast, binding of nicotine to nAChRs located 
on excitatory glutamatergic terminals results in gluta-
mate release, which in turn stimulates dopaminergic 
neurons.  Binding of nicotine to nAChRs located on 
inhibitory GABAergic projections leads to the release 
of gamma aminobutyric acid (GABA), which in turn 
inhibits dopaminergic neurons. Both glutamate and 
GABA neurotransmission play important roles in the 
development of nicotine dependence (for a review, see 
Markou, 2008). nAChRs are also present on neurons 
that release other neurotransmitters, including opioids, 
norepinephrine, serotonin, orexin, and cannabinoids, 
but the role of these neurotransmitter systems in nicotine 
dependence has not been extensively studied.
Nicotinic Receptor Subunits and Nicotine  
Reinforcement
The ability of nicotine to activate a particular nAChR 
depends on the subunits that make up the receptor. 
nAChR subunits exist in 12 isoforms (variant forms), 
labeled α2–α10 and γβ2–β4 (Figure 1; Dani and Ber-
trand, 2007). Every nAChR consists of five subunit 
molecules arranged in a ring around a central channel 
that opens to admit ions when the receptor is activated. 
In some nAChRs, called homomeric nAChRs, all five 
subunits are the same—for example, all are α7. Other 
nAChRs, called heteromeric, have a mix—for example, 
two α4 and three β2 subunits. The mix of subunits in 
each nAChR gives the receptor its distinct pharmaco-
logical properties, including its response to nicotine 
stimulation.
Extensive preclinical evidence suggests that β2-, 
α4-, α5-, α6-, and α7-containing nAChRs mediate the 
reinforcing and behavioral effects of nicotine (Fowler et 
al., 2008; Markou, 2008). Here we briefly summarize 
this evidence (Figure 2):
•	 	β2-containing nAChRs:  Mice that lack the β2 nAChR 
subunit as a result of genetic manipulation, called β2 
knockout mice, do not self-administer nicotine (Pic-
ciotto et al., 1998). However, β2 knockout mice begin 
to self-administer nicotine when the missing receptor 
subunit is introduced into their brains with another 
genetic manipulation. Furthermore, rats treated with a 
compound that blocks the action of nicotine at α4β2-
containing nAChRs self-administer less nicotine than 
control animals given an inert vehicle like saline.
•	α5-containing nAChRs: Mice bred to lack the α5 
subunit (i.e., α5 knockout mice) had fewer nicotine-
induced seizures and attenuated nicotine-induced 
locomotor activity compared with wildtype mice. 
Importantly, α5 knockout mice showed increased 
nicotine self-administration compared with wildtype 
mice. This work by Fowler and colleagues (2011) 
suggests that activity of the α5 subunit in the medial 
habenula-interpeduncular nucleus pathway reduces the 
aversive effects of high doses of nicotine. Humans who 
have a single-nucleotide polymorphism (SNP) in the 
gene for the α5 subunit that decreases the expression of 
the α5-containing nAChRs are twice as likely as those 
without this SNP to develop nicotine dependence. 
Taken together with the animal findings, this pat-
tern of results suggests that agonists of α5-containing 
nAChRs or other compounds that increase the activity 
of α5-containing nAChRs may promote smoking ces-
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(A) Side view of the α7 nAChR showing binding sites for acetylcholine or nicotine. (B) Top 
view of the α7 nAChR showing binding sites. (C) Schematic top views of four nAChR sub-
types, showing their subunit composition: α7 (homomeric); α4β2 (heteromeric);  α3β4 
(heteromeric); α4α6β2β3 (heteromeric). Reproduced with permission from Changeux 
and Taly, 2008.
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•	α6-containing nAChRs: Compounds that selectively 
reduce the activity of α6-containing nAChRs dose-
dependently decrease nicotine self-administration 
in rats, suggesting these nAChRs are important in 
nicotine’s reinforcing effects (Dwoskin et al., 2009). 
•  α7-containing nAChRs: Rats self-administered less 
nicotine after systemic administration of a compound 
that prevents nicotine from interacting with predomi-
nantly homomeric α7-containing nAChRs (Markou 
and Paterson, 2001). These results suggest a role for 
α7-containing nAChRs in the reinforcing effects of 
nicotine.
In summary, activation of nAChRs that contain β2, 
α4, α6, or α7 subunits appears to promote the rein-
forcing effects of nicotine. By contrast, α5-containing 
nAChRs appear to limit nicotine reinforcement, possibly 
by mediating the drug’s aversive effects. An important 
unanswered question is whether every nAChR that 
contains one of these subunits contributes to nicotine 
reinforcement, or whether only subsets of these nAChRs 
are involved. Ultimately, the complete subunit compo-
sition and stoichiometry of nAChRs containing these 
five subunits needs to be fully understood to develop 
medications that will block the reinforcing effects of 
nicotine and promote smoking cessation.
Nicotinic Receptor Subunits and Nicotine  
Withdrawal
Evidence from rodent models and genetically modified 
mice suggests that nAChRs and their various subunits 
mediate the aversive somatic and negative affective 
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FIGURE 2. Pharmacological Strategies to Attenuate Nicotine Reinforcement and Alleviate Withdrawal 
A) Potential targets in the mesolimbic reward system can promote smoking cessation by attenuating the reinforcing effects of nicotine. The reinforcing effects of 
nicotine are partly mediated by the activation of dopamine neurons in the ventral tegmental area (VTA) and the release of dopamine (DA) in the nucleus accum-
bens (NAc). The activity of dopamine neurons in the VTA is regulated by glutamatergic and GABAergic inputs from different brain regions. Pharmacological 
strategies that attenuate the reinforcing effects of nicotine and cue-induced reinstatement of nicotine seeking in animals include compounds that block nicotine 
and acetylcholine from stimulating nACh receptors on glutamate- and dopamine-releasing neurons,  such as nicotinic receptor antagonists and partial agonists; 
compounds that reduce excitatory glutamatergic neurotransmission in the VTA, such as the presynaptic mGlu2/3 receptor agonists/positive modulators, post-
synaptic mGlu5 antagonists/negative modulators, and N-methyl-d-aspartate (NMDA) receptor antagonists; and compounds that increase the influence of the 
inhibitory neurotransmitter GABA at receptors on dopamine neurons such as GABA enhancers and GABAB positive modulators. Compounds that reduce dopa-
minergic neurotransmission, such as DA receptor antagonists, also attenuate nicotine reinforcement and reinstatement in animal models.
B) Potential targets in the mesolimbic reward system may help to alleviate the negative affective symptoms seen in smokers who quit smoking. Chronic nicotine 
exposure results in decreased dopamine and glutamate neurotransmission in the VTA and NAc. Pharmacological compounds that facilitate dopamine and/or 
glutamate release in the VTA and/or NAc alleviate the negative affective effects of nicotine withdrawal in animals. Such compounds/strategies include nicotine 
replacement therapy, nicotine receptor partial agonists, mGlu2/3 receptor antagonists/negative modulators, and dopamine uptake blockers.
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signs of nicotine withdrawal (for reviews, see Kenny 
and Markou, 2001; Fowler et al., 2008). For example, 
nicotine-dependent rats treated with a compound that 
blocks α4β2-containing nAChRs exhibited a negative 
affective or depression-like state, during which they 
were less responsive to electrical stimulation of their 
reward system but showed no somatic signs of nicotine 
withdrawal (Epping-Jordan et al., 1998). 
By contrast, nicotine- dependent rats treated with 
a compound that blocks multiple nAChR subtypes, 
including β4-containing nAChRs, exhibited both a 
depression-like state and somatic signs of nicotine with-
drawal. Importantly, experiments with knockout mice 
suggest that nAChRs containing α5, α7, and β4 subunits 
are instrumental in the expression of somatic signs of 
nicotine withdrawal, whereas β2-containing nAChRs 
contribute to the nicotine withdrawal-induced negative 
affective state (Fowler et al., 2008).
Nicotinic Receptor–Based Treatment Strategies
Developers of antismoking medications have long 
focused on compounds that interact with nAChRs (see 
Table 1). Varenicline, for example, is a partial agonist at 
α4β2-containing nAChRs. Varenicline attenuates the 
reinforcing effects of nicotine by occupying the bind-
ing sites on these receptors and blocking nicotine from 
binding to them. Varenicline and other partial agonists 
also weakly stimulate α4β2-containing nAChRs, thereby 
reducing withdrawal symptoms. 
On the basis of the preclinical literature discussed 
above, compounds that act at nAChRs that contain the 
β2, α5, α7, and β4 subunits have the potential to reduce 
the negative affective and aversive somatic symptoms of 
nicotine withdrawal.
Researchers are also exploring the potential for a 
new generation of smoking-cessation therapies based 
on allosteric modulation of nAChRs (Yoshimura et al., 
2007). Allosteric modulators are compounds that bind 
to sites on the receptor that are different from the sites 
where agonists or antagonists bind. Allosteric modu-
lators do not directly stimulate nAChRs, but instead 
increase or decrease their responsiveness to agonists like 
nicotine or natural neurotransmitters like acetylcholine. 
Researchers have identified several allosteric binding 
MEDICATIONS/ 
COMPOUNDS
MECHANISM STATUS REFERENCE
Nicotine replacement  
therapies*
Replace nicotine obtained 
from tobacco smoke 
through the use of safer 
options
FDA approved Nides, 2008
Varenicline Partial α4β2 nAChR agonist
Acts as an antagonist in 
the presence of nicotine to 
decrease the reinforcing 
effects of nicotine 
Activates nicotinic 
receptors during abstinence 
and limits the aversive 
effects associated with nico-
tine withdrawal
FDA approved Gonzales et al., 2006
Mecamylamine Nonselective nicotinic 
receptor antagonist
Utility limited due to non-
selective action
Schnoll and Lerman, 2006
*Nicotine patch, gum, inhaler, microtab, nasal spray, and lozenge.
TABLE 1. FDA-Approved and Investigational Smoking-Cessation Medications Targeting Nicotinic  
Acetylcholine Receptors
Varenicline’s 
dual actions 
attenuate nico-
tine’s reinforc-
ing effects and 
reduce with-
drawal symp-
toms.sites on nAChRs. Allosteric compounds acting at these 
sites may either help to reduce the reinforcing effects of 
nicotine or may alleviate the aversive effects of nicotine 
withdrawal, or both, and thus may help prevent relapse 
(Taly et al., 2009).
Other promising strategies currently under investiga-
tion aim to inhibit stimulation of nAChRs by reducing 
the amount of nicotine that reaches the brain. These 
include immune-based approaches, such as nicotine 
vaccines and pharmacokinetic treatments that alter 
the availability of nicotine by enhancing its peripheral 
metabolism and clearance (Xi et al., 2009).
NEUROTRANSMITTER SYSTEMS IN NICOTINE 
ADDICTION
As described above, nicotine initiates the processes lead-
ing to nicotine dependence by interacting with nAChRs 
on dopaminergic, glutamatergic, and GABAergic neu-
rons. Accordingly, as discussed, one set of potential 
medication strategies for treating nicotine dependence 
focuses on modulating the nicotine-nAChR interaction. 
A second group of potential strategies targets the receptors 
and transporters that mediate the effects of dopamine, 
glutamate, and GABA after exposure to nicotine.
Dopamine
Dopamine has been strongly implicated in the reinforc-
ing and withdrawal effects of nicotine. The key evidence 
includes experiments in laboratory animals that show:
•  administering nicotine increases dopamine transmis-
sion within the mesolimbic reward system; and
•		administering compounds that block dopamine bind-
ing to its receptors (D1, D2, D3, D4, and D5 recep-
tors) decreases the reinforcing effects of nicotine.
Dopaminergic neurotransmission is decreased during 
nicotine withdrawal. For example, in nicotine-dependent 
rats, the induction of nicotine withdrawal by administra-
tion of the nAChR antagonist mecamylamine resulted in 
decreased dopamine levels in the NAc  compared with 
administration of an insert substance (Hildebrand et 
al., 1998). In addition, the decrease in NAc dopamine 
correlated well with the somatic and affective signs of 
nicotine withdrawal. The decrease in NAc dopamine 
was greater in adult rats compared with adolescent rats 
(Natividad et al., 2010), possibly indicating a more 
important role for mesolimbic dopamine in nicotine 
withdrawal in adult rats compared with adolescent 
rats. Dopamine-based smoking-cessation medications 
that are currently available or under development are 
directed toward either alleviating nicotine withdrawal 
symptoms, blocking nicotine reinforcement, or both 
(see box,Treatment Strategies for Nicotine Dependence 
Based on Dopaminergic Neurotransmission).
Glutamate
Glutamate, the brain’s primary excitatory neurotransmit-
ter, also plays a critical role in the development of nico-
tine dependence (Liechti and Markou, 2008). Nicotine 
increases the release of glutamate by binding to excitatory 
α7-containing nAChRs located on presynaptic terminals 
of glutamatergic neurons in the VTA, NAc, amygdala, 
hippocampus, and PFC (Mansvelder and McGehee, 
2002).The released glutamate binds to ionotropic and 
metabotropic glutamate receptors located on neurons 
in these areas (Figure 2).
Glutamate and nicotine reinforcement
Glutamate released into the VTA after nicotine admin-
istration binds to glutamate  receptors on dopaminergic 
neurons. The resulting increased firing of VTA dopami-
nergic neurons leads to dopamine release in the NAc and, 
consequently, nicotine reward (Grillner and Svensson, 
2000). The rewarding effect of nicotine can be attenu-
ated by administering compounds that reduce glutamate 
TREATMENT STRATEGIES FOR NICOTINE DEPENDENCE 
BASED ON DOPAMINERGIC NEUROTRANSMISSION
Alleviation of withdrawal symptoms by blockade of dopamine uptake 
transporter
Bupropion is approved by the Food and Drug Administration (FDA) as a 
smoking cessation medication. It acts by blocking the uptake of synaptic 
dopamine via the dopamine transporter (DAT). In addition to blocking 
dopamine uptake, bupropion has other potentially therapeutic actions, such 
as blockade of nicotinic acetylcholine receptors and norepinephrine uptake 
(Paterson, 2009). Clinically, bupropion alleviates negative affective symp-
toms associated with smoking cessation, such as depression, difficulty in 
concentrating, and irritability. 
Attenuation of the reinforcing effects of nicotine via blockade of dopa-
mine receptors 
Blocking the reinforcing effects of nicotine using a dopamine receptor 
antagonist is another dopamine-based strategy that can be developed for 
smoking cessation (Figure 2, page 7). Blockade of D1, D2, and D3 dopami-
nergic receptors decreases nicotine self-administration. There is consider-
able interest in D3 receptor antagonists because this subtype of dopamine 
receptors has high affinity for dopamine and is extensively expressed in the 
mesolimbic dopamine system (Diaz et al., 2000). Another reason for the 
interest in D3 dopamine receptors is that D1 and D2 receptor antagonists 
tend to produce adverse effects in humans. 
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transmission. For example, animals self-administered 
less nicotine than control animals when treated with 
compounds that:
•	prevent glutamate from binding to postsynaptic iono-
tropic or metabotropic glutamate receptors, such as 
antagonists at postsynaptic N-methyl-d-aspartate 
(NMDA), AMPA receptors, or mGlu5 receptors 
(Liechti and Markou, 2008).
•  activate presynaptic inhibitory mGlu2/3 receptors.
Furthermore, rats treated with glutamate receptor 
antagonists showed reduced nicotine-induced dopamine 
release compared with rats receiving an inert substance 
(Fu et al., 2000). These findings suggest that decreasing 
glutamate transmission can facilitate smoking cessation 
by decreasing the reinforcing effects of nicotine. 
 
Glutamate and nicotine withdrawal
Withdrawal after chronic nicotine exposure is character-
ized by decreased glutamate transmission and compensa-
tory changes in glutamate receptors (Mansvelder et al., 
2002). For example, rats exhibited decreased expression 
of NMDA ionotropic glutamate receptor subunits, as 
well as decreased functioning of mGlu2/3 receptors in 
the PFC, during early withdrawal following chronic 
nicotine self-administration (Kenny et al., 2009; Liechti 
et al., 2007). Because presynaptic mGlu2/3 receptors 
reduce glutamate release when activated, the decreased 
functioning of mGlu2/3 receptors appears to be a com-
pensatory mechanism to offset the reduction in synaptic 
glutamate levels that occurs during early withdrawal. 
Similarly, rats in early withdrawal after chronic 
nicotine self-administration exhibited downregulation 
of the glutamate transporter (GLT1) in the NAc and 
cystine-glutamate transporter (xCT) in the VTA and 
NAc (Knackstedt et al., 2009). These transport pro-
teins are located on glial cells and have opposite roles 
in the regulation of synaptic glutamate levels. GLT1 
decreases synaptic glutamate by drawing glutamate out 
of the synapse into the glia; by contrast, xCT extrudes 
vesicular glutamate from glia in exchange for synaptic 
cystine. The downregulation of GLT1 and xCT during 
nicotine withdrawal are therefore examples of compen-
satory mechanisms in response to synaptic glutamate 
depletion that occurs after chronic nicotine exposure.
In summary, preclinical data suggest that with-
drawal from chronic nicotine exposure is characterized 
by decreased glutamatergic transmission. Thus, medica-
tions that increase synaptic glutamate levels may help 
to alleviate withdrawal symptoms in abstinent smokers.
Glutamate and cue-induced relapse
As described above, memory associations that link 
certain people, places, and things with the rewarding 
effects of smoking can trigger intense cravings that lead 
to relapse in abstinent smokers. In animals, exposure 
to cues previously associated with nicotine can enhance 
mesolimbic glutamatergic neurotransmission, resulting 
in the resumption of drug-seeking behavior (Kalivas and 
O’Brien, 2008). Treating animals with compounds that 
block glutamatergic neurotransmission suppresses this 
effect  (Liechti and Markou, 2008). Accordingly, one 
strategy to prevent relapse in humans is to administer 
compounds that block glutamatergic neurotransmission.
Unfortunately, learned associations that induce crav-
ing cannot be easily erased. Therefore one approach to 
help smokers maintain abstinence is to replace memo-
ries that link stimuli to smoking and the reward effects 
of nicotine with new memories that will not induce 
craving or raise the risk of relapse (Taylor et al., 2009). 
This type of learning, which decreases the reward value 
of stimuli previously associated with smoking, is called 
extinction learning (Myers et al., 2011). Interestingly, 
increasing glutamate transmission facilitates extinction 
learning. Therefore, another strategy to prevent  relapse 
in abstinent smokers is to aid extinction learning via 
administration of compounds that increase glutamatergic 
neurotransmission.
 
Glutamate-based treatment strategies
Table 2 lists specific glutamate-based strategies that target 
the different glutamatergic receptors and transporters for 
the treatment of nicotine dependence (see also Figure 
2). Major preclinical findings that involve glutamatergic 
substrates are described below (for a more detailed review, 
see Liechti and Markou, 2008):
mGlu2/3 receptors
Administration of an mGlu2/3 receptor agonist in rats 
decreases nicotine self-administration. Furthermore, 
such administration decreased reinstatement of nico-
tine-seeking behavior upon exposure to cues previously 
associated with the effects of nicotine (Liechti et al., 
2007). These findings suggest that mGluR2/3 recep-
tor agonists may help promote smoking cessation and 
prevent relapse in humans. 
However, the attenuating effects of mGlu2/3 receptor 
agonists on  nicotine self-administration in rats waned 
after repeated administration. This loss of effective-
ness suggests the development of tolerance that may 
One approach 
to help smok-
ers maintain 
abstinence 
is to weaken 
and overwrite 
memories that 
link stimuli to 
smoking and 
the rewarding 
effects of nico-
tine. TABLE 2. Potential Therapeutic Utility of Glutamatergic Drugs Based on Preclinical Evidence
POTENTIAL THERAPEUTIC UTILITY
 
GLUTAMATE RECEPTOR
 
COMPOUND(S)/ LIGAND(S)
1 Promote smoking cessation by block-
ing the reinforcing effects of nicotine
mGlu2/3 receptor mGlu2/3 receptor agonists
mGlu2/3 receptor positive allosteric modulators
mGlu5 receptor mGlu5 receptor antagonists
mGlu5 receptor negative allosteric modulators
NMDA receptor Glycine-site partial agonists
Cystine-glutamate 
exchanger
Cystine-glutamate activators, such as N-acetylcysteine
2 Prevent relapse by decreasing the 
aversive effects associated with absti-
nence from nicotine
AMPA receptor AMPA receptor positive modulators
mGlu2/3 receptor mGlu2/3 receptor antagonists
mGlu2/3 receptor negative modulators
3 Prevent relapse by enhancing  
extinction of nicotine-seeking  
behavior
NMDA receptor NMDA receptor co-agonists, such as D-cycloserine
mGlu5 receptor mGlu5 receptor agonists
mGlu5 receptor allosteric positive modulators
4 Prevent relapse by blocking  
reinstatement of nicotine-seeking 
behavior
mGlu2/3 receptor mGlu2/3 receptor agonists
mGlu2/3 receptor allosteric positive modulators
mGlu5 receptor mGlu5 receptor antagonists
mGlu5 receptor allosteric negative modulators
Cystine-glutamate 
exchanger
Cystine-glutamate activator, such as N-acetylcysteine
Glutamate transporter Inhibitors of glutamate transporters, such as  
ceftriaxone
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limit the therapeutic utility of full agonists at mGlu2/3 
receptors. Currently, positive allosteric modulators for 
mGlu2/3 receptors are available and are being evaluated 
clinically for other indications, including treatment of 
schizophrenia. mGlu2/3 receptor positive allosteric 
modulators may prove to be more suitable than the full 
mGlu2/3 receptor agonists. However, the utility of these 
compounds as potential antismoking medications still 
needs to be determined both preclinically and clinically. 
As described above, animals exhibit a depression-like 
state upon withdrawal from chronic nicotine exposure.
That state is attributed to a decrease in glutamatergic 
neurotransmission. In animal studies, administration 
of compounds that increase glutamatergic neurotrans-
mission by blocking presynaptically located inhibitory 
mGlu2/3 receptors reversed the depression-like state 
associated with nicotine withdrawal. Thus, mGluR2/3 
antagonists may be useful for treating the negative affec-12 • ADDICTION SCIENCE & CLINICAL PRACTICE—JULY 2011
tive symptoms resulting from smoking abstinence in 
humans. 
mGlu5 receptors
Administration of compounds that block the mGlu5 
receptors decrease the self-administration of nicotine 
and attenuate the reward-enhancing effects of nico-
tine in rats (Kenny et al., 2003; Paterson et al., 2003), 
suggesting that mGlu5 receptor antagonists decrease 
the reinforcing effects of nicotine. Administration of 
mGlu5 receptor antagonists in rats also blocked the 
reinstatement of nicotine-seeking behavior in response to 
cues previously associated with nicotine, suggesting that 
these compounds may help prevent relapse in humans 
(Markou, 2008). 
However, administration of mGlu5 receptor antago-
nists aggravated the depression-like state and somatic 
signs associated with nicotine withdrawal in rats. Fur-
thermore, at the highest tested dose, mGlu5 receptor 
antagonists on their own induced a depression-like state 
in nicotine-naïve rats. Thus, these compounds may have 
negative affective effects in humans. Taken together, 
these data suggest that, in humans, mGlu5 receptor 
antagonists may promote smoking cessation and prevent 
relapse after a period of abstinence but may worsen the 
symptoms of early nicotine withdrawal. 
Negative allosteric modulators of the mGlu5 receptor 
may prove to be better smoking-cessation aids than full 
antagonists. Compounds of this type are currently being 
clinically evaluated for indications including gastro-
esophageal reflux disease, migraine, and pain. Evaluation 
for potential use as a treatment for nicotine dependence 
is highly warranted.
NMDA receptors
In animals, administration of compounds that reduce 
glutamate neurotransmission by blocking the NMDA 
receptors decreased nicotine self-administration, suggest-
ing that NMDA receptor antagonists can decrease the 
reinforcing effects of nicotine (Kenny et al., 2009). In a 
small study, memantine, a low-affinity NMDA receptor 
antagonist that also blocks some nAChRs, did not reduce 
cigarette smoking or craving in smokers. Unfortunately, 
high-affinity NMDA receptor antagonists are known 
to produce severe adverse neurotoxic and psychogenic 
effects in humans and therefore are unlikely to be devel-
oped into medications for human use.
The structure of the NMDA receptor is quite com-
plex, and its activation requires the binding of both 
glutamate and a co-agonist, such as glycine. Therefore   
glutamate neurotransmission can also be decreased with 
compounds that block the binding of glycine to the 
NMDA receptor. In mice, administration of such a 
compound blocked both the acquisition and expression 
of preference for a nicotine-associated environment in 
a conditioned place preference (CPP) study. This find-
ing suggests that compounds that occupy the glycine 
binding site on the NMDA receptor have the potential 
to decrease the reinforcing effects of nicotine and thus 
may help people quit smoking.
Interestingly, activation of the NMDA receptor 
facilitates extinction learning. There is strong preclinical 
evidence to suggest that administration of D-cycloserine, 
an NMDA receptor co-agonist that subtly activates 
the NMDA receptor, facilitates extinction of learned 
fear responses in animals (Woods and Bouton, 2006). 
D-cycloserine is currently being evaluated as a treat-
ment for people who suffer from extreme anxiety or 
fear (phobias) of certain places and situations in their 
environment (Hofmann et al., 2006). It is hypothe-
sized that D-cycloserine will help these people establish 
new learned associations that will eventually alleviate 
their phobias. In rats, administration of D-cycloserine 
facilitates extinction of cocaine seeking and cocaine-
induced CPP behavior (Myers et al., 2011). Impor-
tantly, in a small preliminary study, smokers who were 
given D-cycloserine had fewer cravings when exposed 
to smoking-related cues than smokers given a placebo 
(Santa Ana et al., 2009). However, these data are very 
preliminary and further investigations are required to 
examine whether D-cycloserine facilitates extinction of 
nicotine-seeking behavior.
AMPA receptors
As described previously, cessation of smoking in humans 
can result in negative affective symptoms, including irri-
tability, changes in mood, and depression. These effects 
cause many abstinent smokers to restart the smoking habit. 
In nicotine-dependent rats, inhibition of glutamatergic 
transmission by a compound that blocks AMPA receptors 
decreased responsiveness to previously rewarding stimuli, 
resulting in the development of a depression-like state 
resembling nicotine withdrawal (Kenny, Gasparini, and 
Markou, 2003). This finding suggests that antagonists 
at the AMPA receptor will worsen the negative affective 
symptoms that result from smoking cessation in humans. 
Thus, conversely, medications that stimulate AMPA 
receptors, such as AMPA receptor agonists or AMPA 
Smokers given 
D-cycloserine 
had fewer  
cravings on 
exposure to 
smoking-
related cues.receptor positive modulators, may alleviate these nega-
tive symptoms. Interestingly, AMPA receptor positive 
modulators have produced antidepressant-like effects in 
animal models of depression (Paul and Skolnick, 2003). 
Such compounds need to be evaluated clinically before 
conclusions can be reached about their potential utility 
as treatments for nicotine dependence.
Glutamate transporters
On the basis of preclinical evidence, it is hypothesized 
that the hypoglutamatergic state resulting from the ces-
sation of tobacco smoking promotes nicotine-seeking 
behavior (Markou, 2007). Therefore, restoring normal 
glutamatergic neurotransmission through manipulation 
of glutamate transporters, such as xCT and GLT1, may 
help smokers maintain abstinence. Consistent with these 
hypotheses, smokers in a small pilot study smoked fewer 
cigarettes when given a compound such as N-acetylcys-
teine compared with smokers who received a placebo; 
alcohol consumption was taken into consideration. 
N-acetylcysteine binds to xCT  and releases glutamate 
into the synapse from intracellular stores in exchange 
for synaptic cystine (Knackstedt et al., 2009). However, 
further clinical work is required to determine if this 
strategy will be effective in promoting smoking cessation 
and preventing relapse in all smokers.
In summary, the function of the neurotransmit-
ter glutamate has considerable promise as a target for 
smoking-cessation medications. In addition, compared 
with ionotropic glutamate receptors, metabotropic glu-
tamate receptors are potentially excellent targets for 
medication development because they are slow-acting, 
populate brain areas involved in reward and emotion, 
subtly modulate glutamate transmission, and are less 
likely to produce undesirable side effects seen with manip-
ulation of fast-acting ionotropic receptors (Markou, 
2007). Furthermore, allosteric modulators that subtly 
modulate the endogenous glutamatergic system, and thus 
produce fewer undesirable effects compared with full 
glutamate receptor agonists and antagonists, appear to 
have a good chance of proving useful in humans (Rudd 
and McCauley, 2005). Although currently there are no 
FDA-approved glutamate-based smoking-cessation 
agents, several of these compounds are being evaluated 
clinically for treatment of psychiatric disorders that are 
associated with high rates of smoking, such as depres-
sion and schizophrenia (Conn and Jones, 2009). These 
studies may shed light on whether these compounds may 
also have effects on cigarette smoking. 
Gamma-Aminobutyric Acid
GABA is the major inhibitory neurotransmitter in the 
mammalian nervous system. An increase in GABA levels 
in the VTA limits reward and reinforcement by reduc-
ing the activity of mesolimbic dopaminergic neurons. 
GABA is released in the VTA by neurons that originate 
in several brain areas, such as the pedunculopontine 
tegmental nucleus, ventral pallidum, and NAc, as well 
as interneurons located within the VTA itself (Kalivas 
and O’Brien, 2008). Endogenous GABA acts via iono-
tropic GABAA and GABAC receptors and metabotropic 
GABAB receptors.
Role of GABA in nicotine reinforcement, withdrawal, 
and relapse
In nicotine-naïve animals, acute nicotine expo-
sure increases GABA release by activating excitatory   
γ4γ2-containing nAChRs that are located on GABAergic 
neurons in the VTA. Thus initially, nicotine-induced 
GABA release limits the rewarding effects of nicotine. 
By contrast, chronic nicotine exposure desensitizes γ4γ2-
containing nAChRs on GABAergic receptors (Mans-
velder and McGehee, 2002). Hypothetically, this desen-
sitization will decrease nicotine-induced GABA release, 
leading to decreased inhibition of VTA dopaminergic 
neurons and increased dopamine release in the NAc 
—and so facilitate the reinforcing effects of nicotine. 
Administration of compounds that increase GABAergic 
neurotransmission decreases both the reinforcing effects 
of nicotine and reinstatement of cue-induced nicotine-
seeking behavior in rats (Markou, 2008; Vlachou et al., 
2011). Thus, treatments that enhance GABA transmis-
sion may prevent relapse to tobacco smoking.
GABA-based treatment strategies
GABA-based drug discovery for smoking cessation has 
focused on increasing GABAergic transmission, either 
by inhibiting the breakdown of GABA or by activating 
GABAergic receptors (Markou, 2008; Figure 2).
Inhibition of GABA breakdown
The levels of GABA can be increased irreversibly by 
inhibiting GABA transaminase, the primary enzyme 
involved in GABA metabolism. In animal studies, admin-
istration of gamma-vinyl GABA (GVG; also referred to 
as vigabatrin), a compound that inhibits GABA transami-
nase, decreased nicotine self-administration and blocked 
both the acquisition and expression of nicotine-induced 
CPP (Dewey et al., 1999). These findings suggest that 
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GVG reduces the reinforcing effects of nicotine. In addi-
tion, GVG dose-dependently lowered nicotine-induced 
increases in NAc dopamine in both nicotine-naïve and 
nicotine-treated rats. On the basis of these findings, 
it appears that GVG may help smokers quit. GVG is 
approved by the FDA for the treatment of infantile 
spasms and is currently used to treat epilepsy in many 
countries. However, its use is associated with serious 
adverse events, such as visual field defects, that may limit 
its utility as a smoking-cessation aid.
GABAB receptor activation
Administration of compounds that activate GABAB 
receptors, such as GABAB receptor agonists, decreased 
nicotine self-administration in rats. Importantly, the 
reduction in nicotine self-administration persisted even 
after repeated administration of the GABAB agonist, 
indicating that little tolerance to its effectiveness had 
developed (Paterson et al., 2005). In the same study, 
GABAB receptor agonists also blocked the reinstatement 
of nicotine-seeking behavior in rats upon re-exposure to 
nicotine-associated cues. Together these results suggest 
that GABAB receptor agonists may promote smok-
ing cessation. Consistent with the above preclinical 
evidence, in a small double-blind clinical study, the 
GABAB receptor agonist baclofen reduced the number 
of cigarettes smoked per day as well as craving associ-
ated with abstinence (Franklin et al., 2009). However, 
GABAB receptor agonist administration in animals also 
resulted in nonspecific effects, such as decreased respond-
ing for nondrug rewards, including food and pleasurable 
electrical brain stimulation, and undesirable effects such 
as severe motor impairment. These preclinical findings 
suggest that GABAB receptor agonists may have limited 
utility for use in humans.
GABAB receptor positive allosteric modulators
Researchers are investigating the effects of modulators 
that bind to allosteric sites on the GABAB receptor and 
enhance the receptor’s responsiveness to GABA. Impor-
tantly, these positive allosteric modulators tend to have 
more subtle effects than full agonists, which bind to 
the same GABAB site as GABA (Guery et al., 2007). 
For example, positive allosteric modulators of GABAB 
receptors do not cause the severe motor impairment 
seen with GABAB receptor agonists.
Administration of positive allosteric modulators 
of GABAB receptors in rats decreased nicotine self-
administration at doses that did not affect respond-
ing for nondrug rewards such as food (Paterson et al., 
2008). Furthermore, positive allosteric modulators of   
GABAB receptors also blocked the cue-induced reinstate-
ment of nicotine-seeking behavior in rats (Vlachou et 
al., 2011). These findings strongly suggest that GABAB 
receptor positive allosteric modulators may help promote 
smoking cessation and prevent relapse in humans. In 
addition, these allosteric modulators may have better 
side-effect profiles than full GABAB receptor agonists.
CONCLUSIONS
Tobacco smoking is a harmful habit that can be targeted 
to bring down both morbidity and future health care 
costs. Significant progress has been made over the last 2 
decades in understanding the neural substrates involved 
in nicotine dependence. This article has reviewed our 
current understanding of nAChRs and the role of nico-
tinic receptor subtypes in nicotine reinforcement and 
dependence. Preclinical work that evaluates the role of 
non-nAChR substrates, such as dopamine, glutamate, 
and GABA, in nicotine reinforcement and dependence 
was also reviewed. Both nAChR-based and non-nAChR-
based smoking-cessation strategies are under various 
stages of development. Although several of these strate-
gies need to be clinically validated, there is much ground 
for hope that the next generation of smoking-cessation 
agents will provide better medications than those cur-
rently available.
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RESPONSE: A QUEST AND A WAGER 
Rick Bevins, Ph.D., Paul Kenny, Ph.D., and Jed Rose, Ph.D.
Paul Kenny:  Dr. Markou’s paper is a good 
overview of where we are in the quest for 
new pharmacological treatments for smok-
ing addiction. The field is focusing mainly 
on the nicotinic receptors and the gluta-
mate and GABA neurotransmitter systems. 
The nicotinic receptors regulate the effects 
of nicotine, and through these receptors, 
nicotine brings both glutamate and GABA 
into play.
Jed Rose:  I think we are far from exploit-
ing the full potential of nicotine itself as a 
replacement for smoking. At present, fewer 
than 10 percent of people using nicotine 
replacement therapy (NRT) achieve long-
term smoking cessation. I think the success 
rate is low because we haven’t yet learned to 
administer nicotine in a way that reproduces 
the full effect of nicotine obtained from 
smoking. Along with acute reinforcement, 
stress reduction, and cognitive enhance-
ment, we also need to address the habit 
component—the constellation of sensory 
cues that develop around inhaling smoke.
Kenny:  Do you believe that it’s a viable 
strategy to consider medications that bypass 
the nicotinic receptor and instead work on 
other systems, like GABA and glutamate, 
that underlie the habitual aspects of smok-
ing behavior?
Rose:  Trying to modulate those down-
stream systems is an important strategy. 
However, I think it will likely be best used 
in combination with improved nicotine 
replacement. The difficulty of having a 
large impact on smoking without doing 
anything at the nicotine receptor should 
not be underestimated.
Rick Bevins:  Combining pharmacological 
treatments with behavioral approaches is a 
must. There may be a place for combining 
medications, for example, targeting reinforc-
ing effects with one and craving with another, 
or using one medication to alleviate the side 
effects of another. Such strategies are hinted 
at in the article but not addressed directly in 
a way that might encourage this approach.
Kenny:   It seems very logical to give people 
the safest therapeutic that we know works, 
which right now would be NRT. And 
then, it seems like a good idea to have as 
many tools as possible to try to help those 
people for whom NRT is less effective. 
So that’s where many of the compounds 
that the authors discuss come in, such as 
metabotropic glutamate receptor agonists 
or GABAB receptor agonists.
Bevins: The nicotine vaccine is another tool. 
One wouldn’t use it with NRT, of course, 
because it prevents nicotine from getting 
to the brain, but it makes a nice adjunct to 
non-nicotine treatments. It doesn’t have 
any central nervous system effects, so what 
you’re hoping it will do, at least in my mind, 
is just to catch people who slip and get them 
back on the abstinence track.
Rose:  I wouldn’t totally rule out the idea 
that there might be creative combinations 
of NRT and nicotine vaccine, perhaps in a 
sequence where we use the former to wean 